Cancer Immunology, Immunotherapy

, Volume 59, Issue 10, pp 1601–1606 | Cite as

The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible “hard” lesions

  • Federico Garrido
  • Ignacio Algarra
  • Angel M. García-Lora
Focussed Research Review


The discovery of tumor antigens recognized by T lymphocytes has stimulated the development of a variety of cancer treatment protocols aimed at enhancing antitumor-specific T cell responses and tumor rejection. However, immunotherapy-mediated regression of established tumors and clearly positive clinical response to such treatment has not been achieved yet despite the induction of T cells directed against tumor antigens. The failure of the modern immunotherapy protocols can be explained by different tumor escape mechanisms that have been defined in various types of malignancy. The loss or downregulation of MHC class I antigens in tumor cells is one of the best analyzed mechanisms. In this review, we show experimental evidence obtained in our laboratory on human tumors and in a mouse cancer model suggesting that the molecular mechanism responsible for the MHC class I alteration in tumor cells might have a crucial impact on tumor recovery of normal H-2/HLA expression during the natural history of tumor development or after immunotherapy. When the preexisting molecular lesion underlying tumor MHC class I alteration is reversible (regulatory or soft), class I expression can be recovered leading to regression of tumor lesion. In contrast, if the HLA class I alteration is irreversible in nature (structural or hard), the lesion will progress killing the host. This is a new vision of the role of MHC class I alteration in tumors that can explain the failure of immunotherapy in a variety of different clinical protocols.


MHC Cancer Immunoselection Hard lesions Soft lesions Immunotherapy 


  1. 1.
    Zou W (2005) Immunosupressive networks in the tumor environment and their therapeutic relevance. Nat Rev Cancer 5:263–274CrossRefPubMedGoogle Scholar
  2. 2.
    Mapara MY, Sykes M (2004) Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22:1136–1151CrossRefPubMedGoogle Scholar
  3. 3.
    Gorelik L, Flavell RA (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7:1118–1122CrossRefPubMedGoogle Scholar
  4. 4.
    Kawamura K, Bahar R, Natsume W, Sakiyama S, Tagawa M (2002) Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors. Cancer Gene Ther 9:109–115CrossRefPubMedGoogle Scholar
  5. 5.
    McKallip R, Li R, Ladisch S (1999) Tumor gangliosides inhibit the tumor-specific immune response. J Immunol 163:3718–3726PubMedGoogle Scholar
  6. 6.
    Munn DH, Mellor AL (2007) Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J Clin Invest 117:1147–1154CrossRefPubMedGoogle Scholar
  7. 7.
    Chaput N, Confori R, Viaud S, Spatz A, Zitvogel L (2008) The Janus face of dendritic cells in cancer. Oncogene 27:5920–5931CrossRefPubMedGoogle Scholar
  8. 8.
    Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC (2010) Regulatory T cells in cancer. Adv Cancer Res 107:57–117CrossRefPubMedGoogle Scholar
  9. 9.
    Beyer M, Schultze JL (2006) Regulatory T cells in cancer. Blood 108:804–811CrossRefPubMedGoogle Scholar
  10. 10.
    Drake CG, Jaffee E, Pardoll DM (2006) Mechanism of immune evasion by tumors. Adv Immunol 90:51–81CrossRefPubMedGoogle Scholar
  11. 11.
    Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL (1993) Natural history of HLA expression during tumour development. Immunol Today 14:491–499CrossRefPubMedGoogle Scholar
  12. 12.
    Garrido F, Ruiz-Cabello F, Cabrera T, Pérez-Villar JJ, López-Botet M, Duggan-Keen M, Stern PL (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89–95CrossRefPubMedGoogle Scholar
  13. 13.
    Marincola FM, Jafee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181–273CrossRefPubMedGoogle Scholar
  14. 14.
    Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, Garrido F (2001) Expression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment. Int J Cancer 94:243–251CrossRefPubMedGoogle Scholar
  15. 15.
    Garrido F, Algarra I (2001) MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 83:117–158CrossRefPubMedGoogle Scholar
  16. 16.
    Maleno I, López-Nevot MA, Cabrera T, Salinero J, Garrido F (2002) Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother 51:389–396CrossRefPubMedGoogle Scholar
  17. 17.
    Rodriguez T, Mendez R, Roberts CH, Ruiz-Cabello F, Dodi IA, Lopez Nevot MA, Paco L, Maleno I, Marsh SG, Pawelec G et al (2005) High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity. Cancer Immunol Immunother 54:141–148CrossRefPubMedGoogle Scholar
  18. 18.
    Pérez B, Benitez R, Fernandez MA, Oliva MR, Soto JL, Serrano S, López Nevot MA, Garrido F (1999) A new beta 2 microglobulin mutation found in a melanoma tumor cell line. Tissue Antigens 53:569–572CrossRefPubMedGoogle Scholar
  19. 19.
    Mendez R, Rodriguez T, Del Campo A, Monge E, Maleno I, Aptsiauri N, Jimenez P, Pedrinaci S, Pawelec G, Ruiz-Cabello F et al (2008) Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines. Cancer Immunol Immunother 57:719–729CrossRefPubMedGoogle Scholar
  20. 20.
    Seliger B, Atkins D, Bock M, Ritz U, Ferrone S, Huber C, Störkel S (2003) Characterization of human lymphocyte antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin Cancer Res 9:1721–1727PubMedGoogle Scholar
  21. 21.
    Aptsiauri N, Carretero R, García-Lora A, Real LM, Cabrera T, Garrido F (2008) Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother 57:1727–1733CrossRefPubMedGoogle Scholar
  22. 22.
    Garrido F, Cabrera T, Apsiauri N (2010) Hard and soft lesions underlaying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 127:249–256PubMedGoogle Scholar
  23. 23.
    Pérez M, Garrido A, Algarra I, Caballero A, Delgado C, Collado MD, Fernandez-Cruz E, Garrido F (1989) H-2 antigens and tumour-associated transplantation antigens in clones derived from a methylcholanthrene-induced BALB/c tumour: their influence on the generation in vitro and in vivo of the specific anti-tumour immune response. Exp Clin Immunogenet 6:204–218PubMedGoogle Scholar
  24. 24.
    Pérez M, Algarra I, Ljunggren HG, Caballero A, Mialdea MJ, Gaforio JJ, Klein G, Kärre K, Garrido F (1990) A weakly tumorigenic phenotype with high MHC class-I expression is associated with high metastatic potential after surgical removal of the primary murine fibrosarcoma. Int J Cancer 46:258–261CrossRefPubMedGoogle Scholar
  25. 25.
    Cabrera T, Maleno I, Collado A, López Nevot MA, Tait BD, Garrido F (2007) Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms. Tissue Antigens 69:264–268CrossRefPubMedGoogle Scholar
  26. 26.
    Algarra I, Öhlen C, Pérez M, Ljunggren HG, Klein G, Garrido F, Kärre K (1989) NK sensitivity and lung clearance of MHC-class-I-deficient cells within a heterogeneous fibrosarcoma. Int J Cancer 44:675–680CrossRefPubMedGoogle Scholar
  27. 27.
    García-Lora A, Algarra I, Gaforio JJ, Ruiz-Cabello F, Garrido F (2001) Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. Int J Cancer 91:109–119CrossRefPubMedGoogle Scholar
  28. 28.
    García-Lora A, Martinez M, Algarra I, Gaforio JJ, Garrido F (2003) MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer 106:521–527CrossRefPubMedGoogle Scholar
  29. 29.
    Sáenz-López P, Gouttefangeas C, Hennenlotter J, Concha A, Maleno I, Ruiz-Cabello F, Cózar JM, Tallada M, Stenzl A, Rammensee HG, Garrido F, Cabrera T (2010) Higher HLA class I expression in renal cell carcinoma than in autologous normal tissue. Tissue Antigens 75:110–118CrossRefPubMedGoogle Scholar
  30. 30.
    Sanchez-Perez L, Kottke T, Diaz RM, Ahmed A, Thompson J, Chong H, Melcher A, Holmen S, Daniels G, Vile RG (2005) Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res 65:2009–2017CrossRefPubMedGoogle Scholar
  31. 31.
    Goldberger O, Volovitz I, Machlenkin A, Vadai E, Tzehoval E, Eisenbach L (2008) Exuberated numbers of tumor-specific T cells result in tumor escape. Cancer Res 68:3450–3457CrossRefPubMedGoogle Scholar
  32. 32.
    Bai XF, Liu JQ, Joshi PS, Wang L, Yin L, Labanowska J, Heerema N, Zheng P, Liu Y (2006) Different lineages of P1A-expressing cancer cells use divergent modes of immune evasion for T-cell adoptive therapy. Cancer Res 66:8241–8249CrossRefPubMedGoogle Scholar
  33. 33.
    Singh R, Paterson Y (2007) Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res 67:1887–1892CrossRefPubMedGoogle Scholar
  34. 34.
    Cabrera T, Lara E, Romero JM, Maleno I, Real LM, Ruiz-Cabello F, Valero P, Camacho FM, Garrido F (2007) HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother 56:709–717CrossRefPubMedGoogle Scholar
  35. 35.
    Carretero R, Romero JM, Ruiz-Cabello F, Maleno I, Rodriguez F, Camacho FM, Real LM, Garrido F, Cabrera T (2008) Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 60:439–447CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Federico Garrido
    • 1
    • 2
  • Ignacio Algarra
    • 3
  • Angel M. García-Lora
    • 1
  1. 1.Servicio de Análisis Clínicos and InmunologíaHospital Universitario Virgen de las NievesGranadaSpain
  2. 2.Departamento de Bioquímica y Biología Molecular III e InmunologíaUniversidad de GranadaGranadaSpain
  3. 3.Departamento de Ciencias de la SaludUniversidad de JaénJaénSpain

Personalised recommendations